These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27833382)

  • 21. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
    Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
    PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia.
    Simicic P; Grgic I; Santak M; Vince A; Lepej SZ
    Microb Pathog; 2019 Nov; 136():103694. PubMed ID: 31446041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6.
    Patiño-Galindo JÁ; Salvatierra K; González-Candelas F; López-Labrador FX
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2402-16. PubMed ID: 26856832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients.
    Khan HU; Khan S; Shah MA; Attaullah S; Malik MA
    PLoS One; 2020; 15(4):e0231480. PubMed ID: 32275694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
    Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
    Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients.
    Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of drug resistance mutations on antiviral agents in HCV patients.
    Liu G; Cai Q; Li Z; Shao X; Luo Q; Zhang X; Zhao Z
    Antivir Ther; 2016; 21(5):369-75. PubMed ID: 25222865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
    Schnell G; Krishnan P; Tripathi R; Beyer J; Reisch T; Irvin M; Dekhtyar T; Lu L; Ng TI; Xie W; Pilot-Matias T; Collins C
    PLoS One; 2018; 13(10):e0205186. PubMed ID: 30286205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.
    Margeridon-Thermet S; Le Pogam S; Li L; Liu TF; Shulman N; Shafer RW; Najera I
    PLoS One; 2014; 9(8):e105569. PubMed ID: 25140696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
    Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
    PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.
    Santos APT; Silva VCM; Mendes-Corrêa MC; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; Castro VFD; Pinho JRR; Moreira RC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e61. PubMed ID: 36197422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
    Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
    Vidal LL; Soares MA; Santos AF
    J Viral Hepat; 2016 Nov; 23(11):840-849. PubMed ID: 26775769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
    Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
    Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
    Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
    J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.